Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Baccarani · SciRah

Researcher profile · Semantic Scholar

M. Baccarani

Share profile

M. Baccarani — researcher profile on SciRah

h-index: 110
Works: 1,282
Citations: 66K

Most-cited papers

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus, M. Baccarani, R. Silver, C. Schiffer +30 more
2020Leukemia1,341 citations Open access
Semantic Scholar
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
A. Hochhaus, R. Larson, F. Guilhot, J. Radich +11 more
2017New England Journal of Medicine1,089 citations Open access
Semantic Scholar
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
J. Cortes, G. Saglio, H. Kantarjian, M. Baccarani +8 more
2016Journal of Clinical Oncology873 citations Open access
Semantic Scholar
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Jordi Cortés, Dong-Wook Kim, J. Pinilla-Ibarz, P. le Coutre +21 more
2018Blood536 citations Open access
Semantic Scholar
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
Markus Pfirrmann, M. Baccarani, S. Saussele, J. Guilhot +7 more
2016Leukemia289 citations Open access
Semantic Scholar
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
J. Lipton, C. Chuah, A. Guerci-Bresler, G. Rosti +22 more
2016The Lancet Oncology245 citations
Semantic Scholar
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.
D. Dorer, R. Knickerbocker, M. Baccarani, J. Cortes +3 more
2016Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis155 citations Open access
Semantic Scholar
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
G. Rosti, F. Castagnetti, G. Gugliotta, M. Baccarani
2017Nature Reviews Clinical Oncology154 citations
Semantic Scholar
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
M. Baccarani, F. Castagnetti, G. Gugliotta, G. Rosti +3 more
2019Leukemia141 citations
Semantic Scholar
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomis
T. Robak, Jie Jin, H. Pylypenko, G. Verhoef +139 more
2018The Lancet Oncology107 citations Open access
Semantic Scholar
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study.
S. Soverini, L. Bavaro, C. De Benedittis, M. Martelli +45 more
2019Blood101 citations Open access
Semantic Scholar
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
Verena S. Hoffmann, M. Baccarani, J. Hasford, F. Castagnetti +29 more
2017Leukemia98 citations Open access
Semantic Scholar
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
M. Deininger, J. Hodgson, N. Shah, J. Cortes +17 more
2016Blood96 citations Open access
Semantic Scholar
The BCR‐ABL1 transcript type influences response and outcome in Philadelphia chromosome‐positive chronic myeloid leukemia patients treated frontline with imatinib
F. Castagnetti, G. Gugliotta, M. Breccia, A. Iurlo +26 more
2017American journal of hematology/oncology91 citations Open access
Semantic Scholar
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
M. Baccarani, E. Abruzzese, V. Accurso, F. Albano +57 more
2019Blood Advances81 citations Open access
Semantic Scholar
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
M. Pfirrmann, R. Clark, W. Prejzner, M. Lauseker +26 more
2020Leukemia77 citations Open access
Semantic Scholar
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
C. Fava, G. Rege‐Cambrin, Irene Dogliotti, M. Cerrano +41 more
2019Haematologica74 citations Open access
Semantic Scholar
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia
G. Martinelli, C. Papayannidis, A. Piciocchi, V. Robustelli +34 more
2021Blood Advances70 citations Open access
Semantic Scholar
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
R. Hehlmann, A. Voskanyan, M. Lauseker, M. Pfirrmann +22 more
2020Leukemia70 citations Open access
Semantic Scholar
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
G. Martinelli, A. Piciocchi, C. Papayannidis, S. Paolini +31 more
201761 citations
Semantic Scholar
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion
M. Breccia, P. Pregno, P. Spallarossa, E. Arboscello +12 more
2017Annals of Hematology52 citations
Semantic Scholar
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib
M. Pfirrmann, Dobromira Evtimova, S. Saussele, F. Castagnetti +8 more
2017Journal of Cancer Research and Clinical Oncology49 citations Open access
Semantic Scholar
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type
M. Baccarani, G. Rosti, S. Soverini
2019Leukemia45 citations
Semantic Scholar
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series
A. Iurlo, S. Galimberti, E. Abruzzese, M. Annunziata +28 more
2017Annals of Hematology37 citations Open access
Semantic Scholar
A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line
F. Castagnetti, F. Di Raimondo, A. De Vivo, A. Spitaleri +28 more
2017American journal of hematology/oncology34 citations Open access
Semantic Scholar
Flai (fludarabine, cytarabine, idarubicin) plus low‐dose Gemtuzumab Ozogamicin as induction therapy in CD33‐positive AML: Final results and long term outcome of a phase II multicenter clinical trial
A. Candoni, C. Papayannidis, G. Martinelli, E. Simeone +6 more
2018American journal of hematology/oncology32 citations Open access
Semantic Scholar
Prognostic Discrimination in "GoodRisk" Chronic Granulocytic Leukemia
J. Sokal, E. Cox, M. Baccarani, S. Tuna +6 more
201732 citations
Semantic Scholar
Health‐related quality of life in patients with chronic myeloid leukemia receiving first‐line therapy with nilotinib
F. Efficace, F. Castagnetti, B. Martino, M. Breccia +21 more
2018Cancer30 citations Open access
Semantic Scholar
Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives
D. Russo, J. García-Gutiérrez, S. Soverini, M. Baccarani
2020Journal of Clinical Medicine29 citations Open access
Semantic Scholar
Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies.
F. Efficace, F. Cottone, Kathrin Sommer, J. Kieffer +14 more
2019Value in Health29 citations Open access
Semantic Scholar
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
M. Lauseker, Katharina Bachl, A. Turkina, E. Faber +18 more
2019American journal of hematology/oncology27 citations Open access
Semantic Scholar
Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies
F. Efficace, M. Breccia, F. Cottone, I. Okumura +4 more
2016Supportive Care in Cancer27 citations
Semantic Scholar
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia
F. Efficace, A. Iurlo, A. Patriarca, F. Stagno +25 more
2020Leukemia and Lymphoma25 citations Open access
Semantic Scholar
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy
S. Luatti, Carmen Baldazzi, G. Marzocchi, Gaia Ameli +10 more
2017OncoTarget24 citations Open access
Semantic Scholar
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS
S. Soverini, M. Martelli, L. Bavaro, C. De Benedittis +20 more
2020Leukemia23 citations
Semantic Scholar
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
G. Gugliotta, F. Castagnetti, M. Breccia, L. Levato +22 more
2022Haematologica21 citations Open access
Semantic Scholar
Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors
F. Castagnetti, G. Gugliotta, M. Bocchia, M. Trawinska +30 more
2019Blood21 citations Open access
Semantic Scholar
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
G. Specchia, P. Pregno, M. Breccia, F. Castagnetti +41 more
2021Frontiers in Oncology20 citations Open access
Semantic Scholar
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study
M. Malagola, A. Iurlo, E. Abruzzese, M. Bonifacio +28 more
2021Cancer Medicine20 citations Open access
Semantic Scholar
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
G. Gugliotta, F. Castagnetti, M. Breccia, F. Albano +24 more
2017Haematologica20 citations Open access
Semantic Scholar
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients
F. Castagnetti, M. Breccia, G. Gugliotta, B. Martino +21 more
2016Haematologica20 citations Open access
Semantic Scholar
Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors
M. Baccarani, R. Gale
2021Leukemia19 citations
Semantic Scholar
PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I
A. Turkina, O. Vinogradova, E. Lomaia, E. Shatokhina +17 more
2019Blood17 citations
Semantic Scholar
Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies
Kathrin Sommer, F. Cottone, N. Aaronson, P. Fayers +9 more
2019Quality of Life Research16 citations
Semantic Scholar
Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia
Verena S. Hoffmann, J. Hasford, M. Deininger, J. Cortes +2 more
2017Journal of Cancer Research and Clinical Oncology15 citations Open access
Semantic Scholar
Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.
H. Kantarjian, F. Giles, K. Bhalla, Javier Pinilla +6 more
2016Journal of Clinical Oncology15 citations
Semantic Scholar
Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy
A. Turkina, O. Vinogradova, E. Lomaia, E. Shatokhina +17 more
2018Blood14 citations Open access
Semantic Scholar
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
M. Baccarani, F. Bonifazi, S. Soverini, F. Castagnetti +5 more
2022Leukemia12 citations Open access
Semantic Scholar
Rotation of nilotinib and imatinib for first‐line treatment of chronic phase chronic myeloid leukemia
G. Gugliotta, F. Castagnetti, M. Breccia, A. Gozzini +25 more
2016American journal of hematology/oncology12 citations Open access
Semantic Scholar
Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib
F. Castagnetti, G. Gugliotta, M. Breccia, F. Stagno +21 more
201612 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Rosti×27
Invite
G. Rosti — researcher profile on SciRah
F. Castagnetti×25
Invite
F. Castagnetti — researcher profile on SciRah
S. Soverini×19
Invite
S. Soverini — researcher profile on SciRah
G. Gugliotta×19
Invite
G. Gugliotta — researcher profile on SciRah

×15

Invite

F. Stagno — researcher profile on SciRah

Invite

F. Pane — researcher profile on SciRah

Invite

G. Saglio — researcher profile on SciRah

Invite

M. Breccia — researcher profile on SciRah

Invite

M. Cavo — researcher profile on SciRah

E. Abruzzese×12

Invite

E. Abruzzese — researcher profile on SciRah

M. Bonifacio×12

Invite

M. Bonifacio — researcher profile on SciRah

Invite

M. Bocchia — researcher profile on SciRah